Prostate cancer detection in men aged 45-49 years in the UK protect (prostate testing for cancer and treatment) trial

Prostate cancer detection in men aged 45-49 years in the UK protect (prostate testing for cancer and treatment) trial

Bibliographic Details
Main Authors:	Hamdy, F, Howson, J, Lane, A, Donovan, J, Neal, D
Format:	Conference item
Published:	2006

Similar Items

The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK
by: Hamdy, F, et al.
Published: (2006)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
by: Lane, J, et al.
Published: (2010)

THE PROTECT TRIAL - EVALUATING THE EFFECTIVENESS OF TREATMENTS FOR CLINICALLY LOCALISED PROSTATE CANCER
by: Lane, J, et al.
Published: (2009)

Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial.
by: Lane, J, et al.
Published: (2007)

The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer (ISRCTN20141297)
by: Lane, J, et al.
Published: (2004)

The protect (prostate testing for cancer and treatment) study: Advanced cases found through a UK screening study
by: Neal, D, et al.
Published: (2006)

Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
by: Brindle, L, et al.
Published: (2006)

The protect trial - Evaluating the effectiveness of treatments for clinically localised prostate cancer and associated molecular and genetic epidemiology studies
by: Lane, J, et al.
Published: (2007)

10-year outcomes in localized prostate cancer.
by: Hamdy, F, et al.
Published: (2017)

ASSOCIATIONS OF SEXUAL DYSFUNCTION WITH LOCALIZED AND ADVANCED PROSTATE CANCER: A CASE-CONTROL STUDY NESTED WITHIN THE UK POPULATION-BASED PROTECT (PROSTATE TESTING FOR CANCER AND TREATMENT) STUDY
by: Collin, S, et al.
Published: (2009)

Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial.
by: Walsh, E, et al.
Published: (2016)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study
by: Rosario, D, et al.
Published: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
by: Rosario, D, et al.
Published: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
by: Rosario, D, et al.
Published: (2012)

10-year outcomes in localized prostate cancer: Authors' reply
by: Hamdy, F, et al.
Published: (2017)

Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
by: Collin, S, et al.
Published: (2009)

Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK.
by: Down, L, et al.
Published: (2011)

Seasonal variation in prostate-specific antigen levels: A large cross-sectional study of men in the UK
by: Down, L, et al.
Published: (2011)

Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer.
by: Moore, A, et al.
Published: (2009)

Ethics of clinical trials from bayesian perspective: randomisation to clinical trials may solve dilemma of treatment choice in prostate cancer.
by: Hamdy, F, et al.
Published: (2003)

The value of repeat serum PSA measurements in the detection of prostate cancer - Experience from the feasibility phase of the UK protect study
by: Hamdy, F, et al.
Published: (2006)

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial
by: Wade, J, et al.
Published: (2015)

Screening for prostate cancer. The case against.
by: Donovan, J, et al.
Published: (2005)

Prostate cancer: screening approaches
by: Donovan, J, et al.
Published: (2005)

Prostate cancer: screening approaches.
by: Donovan, J, et al.
Published: (2005)

Screening for prostate cancer remains controversial.
by: Neal, D, et al.
Published: (2009)

MEN WITH PROSTATE CANCER MAKE POSITIVE DIETARY CHANGES FOLLOWING TREATMENT IN A RANDOMISED TRIAL: A PROSPECTIVE COHORT STUDY
by: Avery, K, et al.
Published: (2012)

ASSOCIATION OF ANTHROPOMETRIC AND LIFESTYLE FACTORS WITH PROSTATE SPECIFIC ANTIGEN (PSA) TRAJECTORIES IN MEN WITH LOCALISED PROSTATE CANCER UNDERGOING ACTIVE MONITORING
by: Burton, A, et al.
Published: (2011)

Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study).
by: Turner, E, et al.
Published: (2011)

Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.
by: Burton, A, et al.
Published: (2013)

Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
by: Macefield, R, et al.
Published: (2009)

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial
by: S. Sanghera, et al.
Published: (2020-10-01)

Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study
by: Young, GJ, et al.
Published: (2017)

Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).
by: Donovan, J, et al.
Published: (2003)

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
by: J. Donovan, et al.
Published: (2003-01-01)

Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study
by: Leal, J, et al.
Published: (2018)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
by: Rosario, D, et al.
Published: (2008)

Associations of folate, vitamin B12, homocysteine, and folate-pathway polymorphisms with prostate-specific antigen velocity in men with localized prostate cancer.
by: Collin, S, et al.
Published: (2010)

Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen
by: Harrison, S, et al.
Published: (2020)

Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.
by: Tilling, K, et al.
Published: (2010)